193 related articles for article (PubMed ID: 21133792)
1. Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease.
Sheppard JD; Scoper SV; Samudre S
J Ocul Pharmacol Ther; 2011 Feb; 27(1):23-7. PubMed ID: 21133792
[TBL] [Abstract][Full Text] [Related]
2. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%.
Sheppard JD; Donnenfeld ED; Holland EJ; Slonim CB; Solomon R; Solomon KD; McDonald MB; Perry HD; Lane SS; Pflugfelder SC; Samudre SS
Eye Contact Lens; 2014 Sep; 40(5):289-96. PubMed ID: 25083776
[TBL] [Abstract][Full Text] [Related]
3. Prospective Randomized Trial Comparing Efficacy of Topical Loteprednol Etabonate 0.5% Versus Cyclosporine-A 0.05% for Treatment of Dry Eye Syndrome Following Hematopoietic Stem Cell Transplantation.
Boynton GE; Raoof D; Niziol LM; Hussain M; Mian SI
Cornea; 2015 Jul; 34(7):725-32. PubMed ID: 25850708
[TBL] [Abstract][Full Text] [Related]
4. The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy.
Su MY; Perry HD; Barsam A; Perry AR; Donnenfeld ED; Wittpenn JR; D'Aversa G
Cornea; 2011 Oct; 30(10):1098-104. PubMed ID: 21407074
[TBL] [Abstract][Full Text] [Related]
5. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment.
Wilson SE; Perry HD
Ophthalmology; 2007 Jan; 114(1):76-9. PubMed ID: 17070588
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye.
Byun YJ; Kim TI; Kwon SM; Seo KY; Kim SW; Kim EK; Park WC
Cornea; 2012 May; 31(5):509-13. PubMed ID: 19730097
[TBL] [Abstract][Full Text] [Related]
7. Loteprednol Etabonate for the Treatment of Dry Eye Disease.
Beckman K; Katz J; Majmudar P; Rostov A
J Ocul Pharmacol Ther; 2020 Sep; 36(7):497-511. PubMed ID: 32391735
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome after topical ciclosporin in severe dry eye disease with a 10-year follow-up.
Straub M; Bron AM; Muselier-Mathieu A; Creuzot-Garcher C
Br J Ophthalmol; 2016 Nov; 100(11):1547-1550. PubMed ID: 26823393
[TBL] [Abstract][Full Text] [Related]
9. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
Toker E; Asfuroğlu E
Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
[TBL] [Abstract][Full Text] [Related]
10. Modulation of Inflammation-Related Genes in the Cornea of a Mouse Model of Dry Eye upon Treatment with Cyclosporine Eye Drops.
Daull P; Barabino S; Feraille L; Kessal K; Docquier M; Parsadaniantz SM; Baudouin C; Garrigue JS
Curr Eye Res; 2019 May; 44(5):476-485. PubMed ID: 30664361
[TBL] [Abstract][Full Text] [Related]
11. [Study on the treatment of dry eye with Loteprednol Etabonate].
Wan PX; Wang XR; Song YY; Li ZY; Duan HC; Zhang W; Liu Z; Wang ZC
Zhonghua Yan Ke Za Zhi; 2012 Feb; 48(2):142-7. PubMed ID: 22490950
[TBL] [Abstract][Full Text] [Related]
12. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
Barber LD; Pflugfelder SC; Tauber J; Foulks GN
Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
[TBL] [Abstract][Full Text] [Related]
13. Comparison of prednisolone acetate and loteprednol etabonate for the treatment of benzalkonium chloride-induced dry eye syndrome in rats.
Beyazyıldız E; Acar U; Beyazyıldız Ö; Pınarlı FA; Albayrak A; Uğurlu N; Tiryaki M; Delibaşi T
J Ocul Pharmacol Ther; 2014 May; 30(4):306-12. PubMed ID: 24494746
[TBL] [Abstract][Full Text] [Related]
14. Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal.
Rao SN
J Ocul Pharmacol Ther; 2011 Dec; 27(6):603-9. PubMed ID: 21999340
[TBL] [Abstract][Full Text] [Related]
15. Prolonged exposure to loteprednol etabonate in human tear fluid and rabbit ocular tissues following topical ocular administration of Lotemax gel, 0.5%.
Glogowski S; Lowe E; Siou-Mermet R; Ong T; Richardson M
J Ocul Pharmacol Ther; 2014 Feb; 30(1):66-73. PubMed ID: 24325539
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of cyclosporine 0.05% eye drops in Stevens Johnson syndrome with chronic dry eye.
Prabhasawat P; Tesavibul N; Karnchanachetanee C; Kasemson S
J Ocul Pharmacol Ther; 2013 Apr; 29(3):372-7. PubMed ID: 23289903
[TBL] [Abstract][Full Text] [Related]
17. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review.
Rajpal RK; Digby D; D'Aversa G; Mah F; Hollander DA; Conway T
J Ocul Pharmacol Ther; 2011 Jun; 27(3):305-8. PubMed ID: 21574815
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis.
Salib GM; McDonald MB; Smolek M
J Cataract Refract Surg; 2006 May; 32(5):772-8. PubMed ID: 16765793
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of topical cyclosporine for the treatment of dry eye disease.
Perry HD; Solomon R; Donnenfeld ED; Perry AR; Wittpenn JR; Greenman HE; Savage HE
Arch Ophthalmol; 2008 Aug; 126(8):1046-50. PubMed ID: 18695097
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of objective tests for dry eye disease: variability over time and implications for clinical trials and disease management.
Sullivan BD; Crews LA; Sönmez B; de la Paz MF; Comert E; Charoenrook V; de Araujo AL; Pepose JS; Berg MS; Kosheleff VP; Lemp MA
Cornea; 2012 Sep; 31(9):1000-8. PubMed ID: 22475641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
